CMS announced a 44% net savings on 15 high-cost drugs under Medicare, effective January 2027, as part of the Inflation ...

As the deadline draws near, the organizations that will succeed under DSCSA are those that understand compliance is not a ...

In today’s Pharma Pulse, the federal government prepares to unveil newly negotiated Medicare prices for 15 high-cost drugs, ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to enhance financial flexibility and ...

Medicare will announce negotiated prices for 15 high-cost drugs, impacting over 67 million beneficiaries. The Inflation ...

A new Pharma Pulse briefing unpacks declining RSV vaccine durability in older adults, AstraZeneca’s $2 billion expansion of its US biologics manufacturing footprint, and the stock-shaking Phase III ...

Manufacturers now face a rapidly evolving landscape where tariffs can shift overnight—from metals to paper to other key ...

Although CNPVs are widely viewed as a valuable opportunity, the criteria for selection remain somewhat opaque. One of the program’s stated goals is to bolster domestic drug production, particularly ...

Abbott's deal shakes up cancer diagnostics, new research confirms pandemic fatigue's impact on public compliance, and more in today’s Pharma Pulse.

AstraZeneca's $2 billion investment in Maryland will expand biologics manufacturing and establish a new clinical-stage ...

In final part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, points out how ...

In today’s demanding clinical development environment—marked by complex protocols, tightened budgets, and heightened scrutiny from regulators, payers, and patients—fragmented trial planning puts ...